Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | HBB | P68871 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666526 | 1.00 | MEN1 (0.58) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| SCHEMBL3398571 | 0.79 | MEN1 (0.51) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| Hydrochloric Acid SCHEMBL2234488 | 0.78 | MAPT (0.53) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| SCHEMBL4650326 | 0.77 | CCNE2 (0.55) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| Phenazopyridine SCHEMBL1221464 | 0.74 | MEN1 (0.93) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| SCHEMBL3266656 | 0.73 | ALDH1A1 (0.75) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| SCHEMBL3079317 | 0.73 | CASP3 (0.53) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| Phenazopyridine SCHEMBL360809 | 0.73 | MEN1 (1.00) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| Phenazopyridine SCHEMBL14340038 | 0.73 | MEN1 (1.00) | MEN1KMT2ATDP1MAPK1CYP3A4 | |
| SCHEMBL4780554 | 0.73 | KMT2A (0.53) | MEN1KMT2ATDP1MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609413-B2 | Neurons, astrocytes and oligodendrocytes differentiated from a mammalian pluripotent or neural stem cells exposed to a pyridine deriviative | RESEARCH DEVELOPMENT FOUNDATION (US) | 2013-12-17 | — | — | US | claimed |
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | claimed |
| US-20110046092-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-02-24 | — | — | US | claimed |
| EP-2235161-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | Research Development Foundation (US) | 2010-10-06 | — | — | EP | claimed |
| WO-2009076529-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2009-06-18 | — | — | WO | claimed |
| EP-0702107-A2 | Process for dyeing melamine-formaldehyde condensation products | BASF Aktiengesellschaft (DE) | 1996-03-20 | — | — | EP | claimed |
| US-8815592-B2 | Methods and compositions related to dopaminergic neuronal cells | RESEARCH DEVELOPMENT FOUNDATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8609413-B2 | Neurons, astrocytes and oligodendrocytes differentiated from a mammalian pluripotent or neural stem cells exposed to a pyridine deriviative | RESEARCH DEVELOPMENT FOUNDATION (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130149717-A1 | METHODS AND COMPOSITIONS RELATED TO DOPAMINERGIC NEURONAL CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | disclosed |
| WO-2011133661-A2 | METHODS AND COMPOSITIONS RELATED TO DOPAMINERGIC NEURONAL CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110046092-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2235161-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | Research Development Foundation (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-0433821-B1 | Reactive dyes having an anchor on basis of alkenylsulfonyl and benzyl compounds as their intermediates | BASF AG (DE) | 1994-09-28 | — | — | EP | disclosed |
| US-5245020-A | Reactive dyes with two or three nitrogen-containing haloheterocycles as reactive system | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-14 | — | — | US | disclosed |
| US-5241055-A | Use in cold pad-batch processing; fixing; fiber bonding; color- and washfastness; monoazo-, disazo-formazan, triphenyldioxazine and metal phthalocyanine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1993-08-31 | — | — | US | disclosed |
| EP-0492236-A1 | Reactive dyes with alkenylsulphonyl or alkinylsulphonyl groups serving as anchor | BASF Aktiengesellschaft (DE) | 1992-07-01 | — | — | EP | disclosed |
| EP-0433821-A1 | Reactive dyes having an anchor on basis of alkenylsulfonyl and benzyl compounds as their intermediates | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0433764-A1 | Reactive dyestuffs with triazin- and chlorobutinyl anchor | BASF Aktiengesellschaft (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0391264-A1 | Reactive dyes with two or three halogen-N-heterocycles as reactive groups | BASF Aktiengesellschaft (DE) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | GRM6, GRM5, GRM7 | MEN1 3871/4885KMT2A 2213/4885TDP1 3148/4885 |
| US-20110046092-A1 | SMALL MOLECULES FOR NEURONAL DIFFERENTIATION OF EMBRYONIC STEM CELLS | NES, DCX, GAP43 | MEN1 4738/4885KMT2A 378/4885TDP1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.